Pharsight

1. List of Rhopressa drug patents

Application	Filing Date	Opposition Party	Legal Status
EP18206195A	2021-08-18	Isarpatent - Patent- und Rechtsanwälte Barth Charles Hassa Peckmann und Partner mbB	Granted and Under Opposition
EP18206195A	2021-08-18	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Granted and Under Opposition
EP18206195A	2021-08-13	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8450344	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US9096569	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US10654844	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US10174017	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US8394826	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Nov, 2030 (7 years from now)
US9931336	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)
US10588901	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)
US9415043	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10532993	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US11021456	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US10882840	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US11618748	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US11028081	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US11185538	AERIE PHARMS INC	Compositions for treating glaucoma or reducing intraocular pressure	Mar, 2034 (10 years from now)

Do you want to check out RHOPRESSA patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2022

Drugs and Companies using NETARSUDIL MESYLATE ingredient

NCE-1 date: 2021-12-18

Market Authorisation Date: 18 December, 2017

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0002	20 Dec, 2021	2		14 Mar, 2034

Strength	Dosage	Availability
EQ 0.02% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

RHOPRESSA family patents

United States

Japan

Australia

European Union

Spain

Canada

China

Netherlands

Hong Kong

2. List of Rocklatan drug patents

Application	Filing Date	Opposition Party	Legal Status
EP18206195A	2021-08-18	Isarpatent - Patent- und Rechtsanwälte Barth Charles Hassa Peckmann und Partner mbB	Granted and Under Opposition
EP18206195A	2021-08-18	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Granted and Under Opposition
EP18206195A	2021-08-13	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8450344	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US9096569	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US10174017	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US10654844	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US8394826	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Nov, 2030 (7 years from now)
US9993470	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)
US9931336	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)
US10588901	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)
US9415043	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10532993	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US11021456	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US10882840	AERIE PHARMS INC	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds	Jul, 2026 (3 years from now)
US11618748	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US11028081	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (6 years from now)
US11185538	AERIE PHARMS INC	Compositions for treating glaucoma or reducing intraocular pressure	Mar, 2034 (10 years from now)
US11197853	AERIE PHARMS INC	Combination therapy	Mar, 2034 (10 years from now)